AU2006329006B2 - Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid - Google Patents

Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid Download PDF

Info

Publication number
AU2006329006B2
AU2006329006B2 AU2006329006A AU2006329006A AU2006329006B2 AU 2006329006 B2 AU2006329006 B2 AU 2006329006B2 AU 2006329006 A AU2006329006 A AU 2006329006A AU 2006329006 A AU2006329006 A AU 2006329006A AU 2006329006 B2 AU2006329006 B2 AU 2006329006B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
isopropyl
methyl
pyrimidin
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006329006A
Other languages
English (en)
Other versions
AU2006329006A1 (en
Inventor
Miha Tomaz Jaklic
Klemen Naversnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of AU2006329006A1 publication Critical patent/AU2006329006A1/en
Application granted granted Critical
Publication of AU2006329006B2 publication Critical patent/AU2006329006B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006329006A 2005-12-20 2006-12-18 Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid Ceased AU2006329006B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SIP200500344 2005-12-20
SI200500344 2005-12-20
PCT/EP2006/012180 WO2007071357A2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid

Publications (2)

Publication Number Publication Date
AU2006329006A1 AU2006329006A1 (en) 2007-06-28
AU2006329006B2 true AU2006329006B2 (en) 2013-02-28

Family

ID=37866173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006329006A Ceased AU2006329006B2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid

Country Status (9)

Country Link
US (1) US20090093499A1 (enExample)
EP (1) EP1968593B1 (enExample)
JP (1) JP5235676B2 (enExample)
CN (1) CN101330919B (enExample)
AU (1) AU2006329006B2 (enExample)
BR (1) BRPI0620629B8 (enExample)
CA (1) CA2630704C (enExample)
EA (1) EA015682B1 (enExample)
WO (1) WO2007071357A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539278A (ja) 2006-09-18 2008-11-13 テバ ファーマシューティカル インダストリーズ リミティド 結晶性ロスバスタチンカルシウム
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548513B1 (en) * 2000-01-26 2003-04-15 Astrazeneca Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
EA008224B1 (ru) * 2001-03-13 2007-04-27 Пенвест Фармасьютикалз Ко. Хронотерапевтические дозированные формы
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
EP1487419A2 (en) * 2002-03-20 2004-12-22 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN1886383A (zh) * 2003-10-22 2006-12-27 兰贝克赛实验室有限公司 无定形罗苏伐他汀钙的制备方法
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
KR100887264B1 (ko) * 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548513B1 (en) * 2000-01-26 2003-04-15 Astrazeneca Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
US20090093499A1 (en) 2009-04-09
AU2006329006A1 (en) 2007-06-28
JP5235676B2 (ja) 2013-07-10
EA015682B1 (ru) 2011-10-31
CN101330919A (zh) 2008-12-24
BRPI0620629B1 (pt) 2020-01-14
JP2009519985A (ja) 2009-05-21
WO2007071357A3 (en) 2007-11-08
EP1968593B1 (en) 2017-08-23
EP1968593A2 (en) 2008-09-17
CA2630704C (en) 2014-08-19
WO2007071357A2 (en) 2007-06-28
CA2630704A1 (en) 2007-06-28
EA200801447A1 (ru) 2008-12-30
CN101330919B (zh) 2012-12-05
BRPI0620629B8 (pt) 2021-05-25
BRPI0620629A2 (pt) 2011-11-16

Similar Documents

Publication Publication Date Title
FI111806B (fi) Farmaseuttisia koostumuksia
EP2021002A2 (en) Pharmaceutical composition
KR20190045286A (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
CA2630704C (en) Pharmaceutical composition
EP2233133B1 (en) Stable Rosuvastatin Compositions
CA2730665A1 (en) Dosage form containing a statin
JP2009519985A5 (enExample)
JP6750785B2 (ja) 安定なロスバスタチンカルシウム錠剤
CN112274487A (zh) 一种瑞舒伐他汀钙药物制剂
MX2008008192A (en) Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino]pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
JP6573098B2 (ja) 安定なロスバスタチンカルシウム錠剤
CN103961354A (zh) 一种稳定的瑞舒伐他汀钙药物组合物及其制备方法
HK1034673A (en) Pharmaceutical compositions
MXPA00007656A (en) Pharmaceutical compositions
HK1108637A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHARMACEUTICAL COMPOSITION COMPRISING (E)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(METHYL(METHYLSULFONYL)AMINO)PYRIMIDIN-5-YL-(3R,5S)-3,5- DIHYDR0XYHEPT-6-ENOIC ACID

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired